These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2907709)

  • 1. Development of acellular pertussis vaccine in Japan.
    Oda M; Higurashi M
    Acta Paediatr Jpn; 1988 Apr; 30(2):136-42. PubMed ID: 2907709
    [No Abstract]   [Full Text] [Related]  

  • 2. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
    Sato Y; Sato H
    Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International symposium on pertussis evaluation and research on acellular pertussis vaccines. National Institute of Health in Tokyo and International Association of Biological Standardization. 14-15 September 1990 at Shizuoka, Japan.
    Biologicals; 1991 Apr; 19(2):145-9. PubMed ID: 1888495
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities.
    Halperin SA; Barreto L; Eastwood BJ; Law B; Roberts EA
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1220-4. PubMed ID: 7921131
    [No Abstract]   [Full Text] [Related]  

  • 5. Type-specific efficacy of acellular pertussis vaccine.
    Aoyama T; Murase Y; Gonda T; Iwata T
    Am J Dis Child; 1988 Jan; 142(1):40-2. PubMed ID: 2893537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine.
    Blumberg DA; Chatfield PC; Cherry JD; Robinson RG; Smith K; Mabie L; Holroyd HJ; Baker LR; Dudenhoeffer FE; Apau N
    Vaccine; 1992; 10(9):614-6. PubMed ID: 1502839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acellular anti-pertussis vaccine].
    Bégué P; Grimpel E; Baron S
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):859-65. PubMed ID: 1819434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further contributions to an improved pertussis vaccine: II. New findings in the development of a pertussis vaccine.
    Robbel L; Hungerer KD; Aktories K
    Behring Inst Mitt; 1984 Nov; (76):110-2. PubMed ID: 6098261
    [No Abstract]   [Full Text] [Related]  

  • 9. [Acellular pertussis vaccine].
    Wiedermann G; Ambrosch F; Vanura H
    Wien Med Wochenschr; 1991; 141(12):270-2. PubMed ID: 1949820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
    Halperin SA; Barreto L; Friesen B; Meekison W
    Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
    Dorji D; Mooi F; Yantorno O; Deora R; Graham RM; Mukkur TK
    Med Microbiol Immunol; 2018 Feb; 207(1):3-26. PubMed ID: 29164393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines.
    Guiso N; Boursaux-Eude C; Weber C; Hausman SZ; Sato H; Iwaki M; Kamachi K; Konda T; Burns DL
    Vaccine; 2001 Apr; 19(23-24):3248-52. PubMed ID: 11312021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. clinical trials with Takeda acellular pertussis vaccine.
    Stout MG
    Tokai J Exp Clin Med; 1988; 13 Suppl():21-8. PubMed ID: 2908521
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
    Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
    Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolation of hemolytic cultures of Bordetella pertussis intended for the production of acellular pertussis preparations and the characterization of their biological properties].
    Miriasova LV; Vasnak'ian IA; Kopaeva TV; Remova TN; Kozhevnikova EV
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Jun; (6):15-8. PubMed ID: 2552711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertussis: the trials and tribulations of old and new pertussis vaccines.
    Cherry JD
    Vaccine; 1992; 10(14):1033-8. PubMed ID: 1471425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer pertussis vaccines on horizon.
    González ER
    JAMA; 1982 Jul; 248(1):22-3. PubMed ID: 6283186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.